Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer By Ogkologos - November 24, 2025 117 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LUNAR study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing MOST POPULAR Hyperfractionated Intensity-Modulated Radiotherapy Decreases the Rate of Severe Late Complications and... March 7, 2023 Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity... December 5, 2022 EMA Recommends Granting a Marketing Authorisation for Melphalan October 1, 2020 Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... November 26, 2019 Load more HOT NEWS Time to get stratified Spotlight On: Exercise Physiologists in Cancer Care Coronavirus reports: “As a Black man with advanced prostate cancer, who... Workout Wednesday – Upper Body Stretches
